UNITED STATES PATENT AND TRADEMARK OFFICE

_____

BEFORE THE PATENT TRIAL AND APPEAL BOARD

_____

MILTENYI BIOMEDICINE GmbH and MILTENYI BIOTEC INC.
Petitioners,

v.

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Patent Owner.

_____

IPR 2022-00852
Patent 9,518,123

_____

IPR 2022-00855
Patent 9,540,445

_____

PATENT OWNER'S EXHIBIT LIST

Ex.	Reference
2001	Jason Fagone, *Has Carl June Found a Key to Fighting Cancer?*, PHILA. MAG. (Aug. 1, 2013).
2002	Denise Grady, *An Immune System Trained to Kill Cancer*, N.Y. TIMES (Sept. 12, 2011), https://www.nytimes.com/2011/09/13/health/13gene.html.
2003	Jasone Fagone, *Walt Keller, Leukemia Survivor, Has Passed*, PHILA. MAG. (Feb. 20, 2014), https://www.phillymag.com/news/2014/02/20/walt-keller-leukemia-survivor-obituary-1953-2014/.
2004	Gina Kolata, *A Cancer Treatment Makes Leukemia Vanish, but Creates More Mysteries*, N.Y. TIMES (Feb. 2, 2022), https://www.nytimes.com/2022/02/02/health/leukemia-car-t-immunotherapy.html.
2005	Denise Grady, *In Girl's Last Hope, Altered Immune Cells Beat Leukemia*, N.Y. TIMES (Dec. 9, 2012), https://www.nytimes.com/2012/12/10/health/a-breakthrough-against-leukemia-using-altered-t-cells.html.
2006	Denise Grady, *F.D.A. Approves First Gene-Altering Leukemia Treatment, Costing $475,000*, N.Y. TIMES (Aug. 30, 2017), https://www.nytimes.com/2017/08/30/health/gene-therapy-cancer.html.
2007	FOOD AND DRUG ADMIN., FDA APPROVAL BRINGS FIRST GENE THERAPY TO THE UNITED STATES (Aug. 30, 2017), https://www.fda.gov/news-events/press-announcements/fda-approval-brings-first-gene-therapy-united-states.
2008	FOOD AND DRUG ADMIN., BREAKTHROUGH THERAPY (Jan. 4, 2018), https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy.
2009	FOOD AND DRUG ADMIN., PRIORITY REVIEW (Jan. 4, 2018), https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review.

2010	Barbara Savoldo et al., *CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients*, 121 J. CLINICAL INVESTIGATION 1822 (2011).
2011	Brian G. Till et al., *Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells*, 112 BLOOD 2261 (2008).
2012	Renier J. Brentjens et al., *Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias*, 118 BLOOD 4817 (2011).
2013	Renier Brentjens et al., *Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial*, 18 MOLECULAR THERAPY 666 (2010).
2014	Renier J. Brentjens et al., *A Phase I Trial for the Treatment of Chemo refractory Chronic Lymphocytic Leukemia with CD19-Targeted Autologous T Cells*, 16 MOLECULAR THERAPY S15 (2008).
2015	Jennifer Couzin-Frankel, *The dizzying journey to a new cancer arsenal*, 340 SCI. 1514 (2013).
2016	Jennifer Couzin-Frankel, *Breakthrough of the Year 2013: Cancer Immunotherapy*, 342 SCI. 1432 (2013).
2017	David L. Porter et al., *Chimeric Antigen Receptor Modified T Cells Directed Against CD 19 (CTL0l 9 cells) Have Long-Term Persistence And Induce Durable Responses In Relapsed, Refractory CLL*, 122 BLOOD 4162 (2013).
2018	David L. Porter et al., *Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD 19 (CTL019) In Patients With Relapsed Refractory CLL*, 122 BLOOD 873 (2013).
2019	Stephan A. Grupp et al., *T Cells Engineered With A Chimeric Antigen Receptor (CAR) Targeting CD 19 (CTL0l 9) Produce Significant In Vivo Proliferation, Complete Responses And Long-Term Persistence*

	Without GVHD In Children And Adults With Relapsed, Refractory ALL, 122 BLOOD 67 (2013).
2020	James N. Kochenderfer et al., *B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD 19 chimeric-antigen-receptor transduced T cells*, 119 BLOOD 2709 (2012).
2021	*Carl June Named One of Time's 100 Most Influential People in the World*, PENN MEDICINE (Apr. 26, 2018), https://pathology.med.upenn.edu/news/carl-june-named-one-times-100-most-influential-people-world.
2022	Holly Auer, *Penn Medicine Immunotherapy Pioneer Carl June, MD, Awarded 2015 Paul Ehrlich and Ludwig Darmstaedter Prize*, PENN TODAY (Mar. 11, 2015), https://penntoday.upenn.edu/news/penn-medicine-immunotherapy-pioneer-carl-june-md-awarded-2015-paul-ehrlich-and-ludwig-darmstaed.
2023	Andrew Pollock, *Setting the Body's 'Serial Killers' Loose on Cancer*, N.Y. TIMES (Aug. 1, 2016), https://www.nytimes.com/2016/08/02/health/cancer-cell-therapy-immune-system.html.
2024	*2015 Watanabe Award Winner Carl H. June*, IND. CLINICAL AND TRANSLATIONAL SCIS. INST., https://indianactsi.org/awards/watanabe-award-winners/2015-watanabe-award-winner-carl-h-june/ (last visited July 12, 2022).
2025	*Agilent Presents Thought Leader Award to Drs. Carl H. June and Michael Milone*, AGILENT TECHS. INC. (Nov. 17, 2020), https://www.agilent.com/about/newsroom/presrel/2020/17nov-ca20030.html.
2026	Information Disclosure Statement Initialed by Examiner (Apr. 18, 2016), U.S. Patent Application No. 14,997,136.
2027	Information Disclosure Statement Initialed by Examiner (Apr. 18, 2016), U.S. Patent Application No. 14,997,136.

2028	World Intell. Prop. Org. Patent Application No. WO 02/077029 A2.
2029	*Pilot Study for Patients with Chemotherapy Resistant or Refractory CD19 Leukemia and Lymphoma (CART-19)*, CLINICALTRIALS.GOV (April 29, 2009), [http://web.archive.org/web/20090903002304/http://clinicaltrials.gov/ct2/show/NCT00891215].
2030	Amendments to the Claims (Nov. 13, 2018), U.S. Patent Application No. 15,353,899.
2031	Steven A. Rosenberg et al., *Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma*, 319 NEW ENG. J. MED. 1676 (1988).
2032	Michael C. Jensen et al., *Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans*, 16 BIOLOGY BLOOD AND MARROW TRANSPLANTATION 1245 (2010).
2033	Richard A. Morgan et al., *Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2*, 18 MOLECULAR THERAPY 843 (2010).
2034	David L. Porter et al., *A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation*, 107 BLOOD 1325 (2006).
2035	Grazyna Lipowska-Bhalla, *Targeted immunotherapy of cancer with CAR T cells: achievements and challenges*, 61 CANCER IMMUNOLOGY, IMMUNOTHERAPY 953 (2012).
2036	*Latest paper from the father of CAR-T: CAR-T really completely cured cancer*, MEDICALTREND.ORG, https://medicaltrend.org/2022/02/03/latest-paper-from-the-father-of-car-t-car-t-really-completely-cured-cancer/ (last visited July 13, 2022).
2037	Bipulendu Jena et al., *Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor*, 116 BLOOD 1035 (2010).

2038	Michael H. Kershaw et al., *A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer*, 12 CLINICAL CANCER RSCH. 6106 (2006).
2039	Cor H.J. Lamers et al., *Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical Experience*, 24 J. CLINICAL ONCOLOGY e20 (2006).
2040	*ASH honors Bruce R. Blazar, M.D., and Carl H. June, M.D., with 2012 Ernest Beutler Lecture and Prize*, SCIENCEX (Aug. 27, 2012), https://sciencex.com/wire-news/107531358/ash-honors-bruce-r-blazar-md-and-carl-h-june-md-with-2012-ernest.html.
2041	Renier J. Brentjens et al., *Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts*, 13 CLINICAL CANCER RSCH. 5426 (2007).
2042	U.S. Patent No. 7,402,431.
2043	*Cancer treatment myths: Any truth to these common beliefs?*, MAYO CLINIC (March 22, 2022), https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/cancer/art-20046762.
2044	Adam Bagg Aff., July 19, 2022.
2045	*SITC Smalley Award 2013 Recipient*, SOC'Y FOR IMMUNOTHERAPY OF CANCER, https://www.sitcancer.org/funding/named-funds-and-awards2/smalley/2013 (last visited July 19, 2022).
2046	*AAI-Steinman Award for Human Immunology Research Past Recipients*, AM. ASS'N OF IMMUNOLOGISTS, https://www.aai.org/Awards/Career-Awards/AAI-Steinman-Award-for-Human-Immunology-Research/Past-Recipients.aspx (last visited July 19, 2022).
2047	File History of the '445 Patent.
2048	Decl. of Thomas S. Fletcher, Nov. 8, 2022.

2049	*Search Results of Clinical Trials Associated with Dr. Richard P. Junghans*, CLINICALTRIALS.GOV (Jan. 12, 2023), https://beta.clinicaltrials.gov/search?distance=SO&term=Richard Junghans.
2050	*Recombinant DNA Advisory Committee Minutes of Meeting*, US DEP'T OF HEALTH & HUM. SERVS., (Feb. 10, 2003).
2051	*Recombinant DNA Advisory Committee Minutes of Meeting*, US DEP'T OF HEALTH & HUM. SERVS., (Mar. 16, 2005).
2052	Hildegund C.J. Ertl et al., *Considerations for the Clinical Application of Chimeric Antigen Receptor (CAR) T Cells: Observations from a Recombinant DNA Advisory Committee (RAC) Symposium June 15, 2010*, 71 CANCER RES. 1 (2011).
2053	Augusto C. Ochoa et al., *Immune Defects in T Cells From Cancer Patients: Parallels in Infectious Diseases, in* CURRENT CLINICAL ONCOLOGY: CANCER IMMUNOTHERAPY AT THE CROSSROADS: HOW TUMORS EVADE IMMUNITY AND WHAT CAN BE DONE 35 (J. H. Finke & R. M. Bukowski eds., 2004).
2054	Peter S. Kim et al., *Features of responding T cells in cancer and chronic infection*, 22 CURRENT OPINION IN IMMUNOLOGY 223 (2010).
2055	Marta Czesnikiewicz-Guzik et al., *T cell subset-specific susceptibility to aging*, 127 CLINICAL IMMUNOLOGY 107 (2008).
2056	Jonathan E. Benjamin et al., *Biology and clinical effects of natural killer cells in allogeneic transplantation*, 22 CURRENT OPINION IN ONCOLOGY 130 (2010).
2057	Elisabeth Ersvaer et al., *Intensive chemotherapy for acute myeloid leukemia differentially affects circulating T_C1, T_H1, T_H17 and T_{REG} cells*, 11 BMC IMMUNOLOGY 1 (2010).
2058	Miroslaw J. Szczepanski, *Increased Frequency and Suppression by Regulatory T Cells in Patients with Acute Myelogenous Leukemia*, 15 CLINICAL CANCER RSCH. 3325 (2009).
2059	Sabine Mumprecht et al., *Programmed death 1 signaling on chronic myeloid leukemia–specific T cells results in T-cell exhaustion and disease progression*, 114 BLOOD 1528 (2009).
2060	Gideon Gross et al., *Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity*, 86 IMMUNOLOGY 10024 (1989).

2061	Anna Kruschinski et al., *Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas*, 105 PROC. OF THE NAT'L ACAD. OF THE SCIS. 17481 (2008).
2062	Olan Dolezal et al., *ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in V_L to V_H orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers*, 13 PROTEIN ENG'G 565 (2000).
2063	Michael C. Milone et al., *Chimeric Receptor Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo: Supplementary Materials and Methods*, 17 MOLECULAR THERAPY 1453 (2009).
2064	T. Sutlu et al., *Natural killer cell-based immunotherapy in cancer: current insights and future prospects*, 266 J. INTERNAL MED. 154 (2009).
2065	Chihaya Imai et al., *Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells*, 106 BLOOD 376 (2005).
2066	Curriculum Vitae of Robert S. Negrin, M.D. (Feb. 10, 2023).
2067	Hollie J. Pegram et al., *Adoptive Transfer of Gene-Modified Primary NK Cells Can Specifically Inhibit Tumor Progression In Vivo*, 181 THE J. IMMUNOLOGY 3449 (2008).
2068	Loredana Ruggeri et al., *Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants*, 295 SCI. 2097 (2002).
2069	Güllü Görgün et al., *Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells*, 115 J. CLINICAL INVESTIGATION 1797 (2005).
2070	Transcript of Deposition of Richard P. Junghans, Ph.D., M.D. (Jan. 13, 2023).
2071	Declaration of Robert S. Negrin, M.D. (Feb. 13, 2023).
2072	John Carroll, *Novartis may still be grappling with Kymriah sales, but historic CAR-T promise still shines through 5-year data*, ENDPOINTSNEWS (June 13, 2022), https://endpts.com/novartis-may-still-be-grappling-with-kymriah-sales-but-historic-car-t-promise-still-shines-through-5-year-data/.

2073	Veronique Blanc et al., *SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies*, 17 CLINICAL CANCER RSCH. 6448 (2011).
2074	Robert T. Abraham et al., *Jurkat T cells and development of the T-cell receptor signalling paradigm*, 4 NATURE REVS. IMMUNOLOGY 301 (2004).
2075	Rebekah R. Bartelt et al., *Comparison of T Cell Receptor-Induced Proximal Signaling and Downstream Functions in Immortalized and Primary T Cells*, 4 PLOS ONE 1 (2009).
2076	Zhaosheng Lin et al., *Comparative Microarray Analysis of Gene Expression During Activation of Human Peripheral Blood T Cells and Leukemic Jurkat T Cells*, 83 LAB'Y INVESTIGATION 765 (2003).
2077	Louis Gioia et al., *A genome-wide survey of mutations in the Jurkat cell line*, 19 BMC GENOMICS 1 (2018).
2078	Michael C. Milone et al., *Corrigendum to "Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo,"* 23 MOLECULAR THERAPY 1278 (2015).
2079	*Kymriah®: Highlights of Prescribing Information*, NOVARTIS PHARMS. CORP. (May 2022).
2080	Jacqueline Corrigan-Curay et al., *T-Cell Immunotherapy: Looking Forward*, 22 MOLECULAR THERAPY 1564 (2014).
2081	Steven C. Katz et al., *Phase I Hepatic Immunotherapy for Metastases study of intra-arterial chimeric antigen receptor modified T cell therapy for CEA+ liver metastases*, 21 CLINICAL CANCER RSCH. 1 (2015).

Certification of Service Under 37 C.F.R. § 42.6(e)(4)

The undersigned hereby certifies that Patent Owner's Exhibit List was served in its entirety by filing through the Patent Trial and Appeal Case Tracking System (P-TACTS), as well as providing a courtesy copy via e-mail to the following attorneys of record for Petitioners listed below:

Yite John Lu	PTABDocketL2Y7@orrick.com
Gary N. Frischling	PTABDocketG2F1@orrick.com

Date: February 13, 2023

By: /Jessamyn S. Berniker/

Reg. No. 72,328